Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | HTR6 | P50406 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428458 | 0.90 | SLC6A4 (0.62) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL14161475 | 0.86 | HTR2A (0.57) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL20665499 | 0.85 | HTR2A (0.56) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL18400731 | 0.83 | HTR2A (0.55) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL14168906 | 0.83 | HTR2A (0.54) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL73842 | 0.81 | MEN1 (0.62) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL11338192 | 0.81 | HTR2A (0.55) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL91128 | 0.79 | HTR2A (0.72) | HTR2ACYP3A4HTR2CHTR6CYP2D6 | |
| SCHEMBL29414676 | 0.79 | HTR2A (0.72) | HTR2ACYP3A4HTR2CHTR6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-11666539-B2 | Synthetic lipid-like materials for brain delivery | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666539-B2 | Synthetic lipid-like materials for brain delivery | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220323369-A1 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | TRUSTEES OF TUFTS COLLEGE | 2022-10-13 | — | — | US | disclosed |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | THE ROCKEFELLER UNIVERSITY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | HTR2A 298/4885CYP3A4 2367/4885HTR2C 309/4885 |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | CCKAR, CCKBR, GRPR | HTR2A 339/4885CYP3A4 1582/4885HTR2C 141/4885 |
| US-20220323369-A1 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | NPC1L1, FABP7, LIPA | HTR2A 2253/4885CYP3A4 470/4885HTR2C 2699/4885 |
| US-11339184-B2 | Antibacterial compounds, compositions thereof, and methods using same | CLPP, MPO, SPOUT1 | HTR2A 4766/4885CYP3A4 4357/4885HTR2C 4844/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HTR2A 4267/4885CYP3A4 4595/4885HTR2C 4547/4885 |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | TNNC1, TNNI3, PYGM | HTR2A 3189/4885CYP3A4 636/4885HTR2C 2955/4885 |
| US-11666539-B2 | Synthetic lipid-like materials for brain delivery | NPC1L1, FABP7, LIPA | HTR2A 2246/4885CYP3A4 460/4885HTR2C 2658/4885 |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | LSS, NRDC, SPOUT1 | HTR2A 4862/4885CYP3A4 3967/4885HTR2C 4866/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | HTR2A 4858/4885CYP3A4 4470/4885HTR2C 4844/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | HTR2A 611/4885CYP3A4 395/4885HTR2C 325/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | HTR2A 4857/4885CYP3A4 4819/4885HTR2C 4874/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HTR2A 4857/4885CYP3A4 4819/4885HTR2C 4874/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | HTR2A 2453/4885CYP3A4 2109/4885HTR2C 1419/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | HTR2A 298/4885CYP3A4 2367/4885HTR2C 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.